Target overview
Synonyms
Nectin-4|NECTIN4
Emerging Competitive
Nectin-4 / NECTIN4
Nectin-4 / NECTIN4 is flagged as emerging competitive based on 17 active trials across 16 sponsors and 0 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 18
Active trials: 17
Recruiting trials: 11
Known assets: 1
Sponsor activity
Competitive footprint
Unique sponsors: 16
Top sponsors: Mayo Clinic | Eli Lilly and | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Tumor types: Stage IV Bladder Cancer AJCC v8 | Locally Advanced Bladder Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma
Patent-density signal summary
Patent layer
Signal count: 0
Recent signals: 0
Top assignees: Unknown
Signal types: Unknown
Scores and labels
Deterministic summary
Clinical crowding: 4/5 (High)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 0/5 (Low)
Momentum: 3/5 (Rising)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.